Abstract
Background Neurocognitive impairment linked to head impact exposure in otherwise healthy, non-concussed athletes may be associated with adverse long-term outcomes. The primary purpose of this study was to evaluate whether a dietary supplement, SynaquellTM, supports brain function and structure in male Junior A ice hockey players over the course of a season.
Methods Players underwent pre-season testing, were randomized into a placebo or dietary supplement group, then were retested after the season. Objective tests included: NeuroCatch® portable evoked potential platform, King-Devick Test of rapid number naming, and blood biomarker assay for neurofilament light chain (NfL).
Results Multivariate analysis revealed significant differences in neurocognitive changes between groups from pre to postseason after controlling for covariates related to head impact exposure. Post-hoc tests showed significant within-subject differences between groups from pre- to post-season in both N100 latency (p = 0.005) and King-Devick score (p = 0.043). Univariate tests of the NeuroCatch results replicated prior findings of a N400 amplitude decrease (p = 0.017) and N100 latency increase (p = 0.049) in the placebo group, but not in the dietary supplement group.
Conclusions This prospective, randomized trial showed that, compared to the placebo group, a multi-ingredient dietary supplement significantly affected objective measures of brain function and structure in Junior A ice hockey players from pre- to post-season. Further investigation into the effects of dietary supplementation on the contact athlete’s brain is warranted.
Competing Interest Statement
M. Stuart has received research grants from the USA Hockey Foundation; RD, SF, and TF are with HealthTech Connex, who provided the NeuroCatch® Platform, with disclosed financial interests; no other relationships or activities that could appear to have influenced the submitted work.
Clinical Trial
NCT05041192
Funding Statement
The study was funded by the USA Hockey Foundation (M. Stuart). The NeuroCatch® Platform was provided by HealthTech Connex. Thorne provided the two study-related products (Synaquell and placebo).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Mayo Clinic gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data from this study are available upon request from the corresponding author.
